1. ALLA AKTIER
  2. NYHETER
  3. XINTELA

Xintela

Nyheter Xintela Nyheter alla bolag

Xintela Year-end report 2022

MARKN.

Summary of the year-end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group

Fourth quarter 2022 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 23,384 (loss: 18,013).
Loss per share* was SEK 0.09 (loss: 0.20).
 
Twelve months 2022 for the group
Income amounted to TSEK 0 (0).
Loss before and after tax totalled TSEK 73,165 (loss: 60,604).
Loss per share* was SEK 0.37 (loss: 0.72).
 
Fourth quarter 2022 for the parent company
Income amounted to TSEK 6 288 (0).
Loss before and after tax totalled TSEK 7,323 (loss: 12,343).
Loss per share* was SEK 0.07 (loss: 0.30).
 
Twelve months 2022 for the parent company
Income amounted to TSEK 6 288 (0).
Loss before and after tax totalled TSEK 44,906 (loss: 58,394).
Loss per share* was SEK 0.25 (loss: 0.65).
At December 31, 2022, the equity/assets ratio** was 66 % (16).


Significant events in the forth quarter of 2022
Notice to Extraordinary General Meeting of Xintela AB (publ). (October 26, 2022)
Xintela secures financing of SEK 25 million and decides on a targeted issue of convertibles. (October 26, 2022)
Xintela proposes Thomas Eldered as new Board member. (October 31, 2022)
Xintela starts next dose level of XSTEM in knee osteoarthritis clinical sudy. (November 9, 2022)
Targinta plans Phase 0 clinical study. (November 24, 2022)
Bulletin from the Extraordinary General Meeting in Xintela AB (publ). (November 28, 2022)
Xintela obtains US patent for stem cell treatment. (December 6, 2022)
Xintela and NorthX Biologics sign collaboration framework agreement. (December 14, 2022)

The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments

Xintela 2022 Year End Report

Datum 2023-02-24, kl 13:15
Källa MFN
Bifogade filer
Xintela 2022 Year End Report
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet